A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy (COVIDTrach)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04572438 |
Recruitment Status :
Completed
First Posted : October 1, 2020
Last Update Posted : May 18, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Tracheostomy Complication Covid19 Ventilator Lung | Procedure: Tracheostomy |
COVID-19 can lead to a severe respiratory illness with 5-12% requiring mechanical ventilation.Standard UK intensive care practice is to consider a tracheostomy after 7-10 days of mechanical ventilation in order to facilitate weaning, reduce duration of mechanical ventilation, shorten intensive care stay and reduce complications relating to prolonged presence of an endotracheal tube. Given the severity of respiratory illness and a mortality in mechanically ventilated COVID 19 patients which exceeds 50%, the benefit of tracheostomy in this group is uncertain.
There are also unique considerations regarding health care professional (HCP) safety when performing tracheostomy in COVID-19 patients due to the potential of aerosol generation and transmission of the infection. ENT UK and other organisations have issued guidance regarding surgical tracheostomy in terms of timing, environment, technique and level of personal protective equipment (PPE). The ability of hospital departments to follow this guidance and the effectiveness of these measures is unknown.
This UK national cohort study aims to assess the effects of tracheostomy in mechanically ventilated COVID-19 patients in terms of the duration of mechanical ventilation, length of ICU and hospital stay and mortality. These data will be related to COVID-19 patients who are mechanically ventilated but do not undergo tracheostomy, as captured by the UK Intensive Care National Audit and Research Centre (ICNARC).
In parallel we will collect data on the tracheostomy procedure itself and compare these to national guidance on tracheostomy in patients diagnosed with COVID-19, and on COVID-19 infections in the surgical and medical teams involved in the tracheostomy procedure.
This proposal builds upon the ongoing COVIDTrach project that has captured data on 550 COVID-19 tracheostomies from 78 NHS hospitals throughout the UK so far. COVIDTrach has successfully brought together surgical, intensive care and anaesthetic specialists to capture early timepoints following tracheostomy. Moving forward, we will work with speech and language therapists and physiotherapists to capture later stages in the patient pathway. This will provide a unique and comprehensive assessment of the role of tracheostomy in COVID-19 patients. It will lay the foundation for further much needed multidisciplinary research into the role of tracheostomy in respiratory disease beyond the COVID-19 pandemic.
Study Type : | Observational |
Actual Enrollment : | 2234 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | COVIDTrach; a UK National Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy |
Actual Study Start Date : | August 1, 2020 |
Actual Primary Completion Date : | October 1, 2021 |
Actual Study Completion Date : | October 1, 2021 |

- Procedure: Tracheostomy
Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
- Time to wean [ Time Frame: 12 months ]Clinical outcome in terms of time in days from tracheostomy to successful weaning from mechanical ventilation.
- Airway related outcomes [ Time Frame: 12 months ]Clinical outcome in terms of length of time from tracheostomy to tracheostomy decannulation.
- Complications [ Time Frame: 12 months ]Clinical outcome in terms of tracheostomy related complications in terms of bleeding, displaced tube, blocked tube, other.
- Length of stay [ Time Frame: 12 months ]Clinical outcome in terms of length of stay at intensive care and total length of stay in hospital in days.
- Mortality [ Time Frame: 12 months ]Clinical outcomes in terms of patient mortality during or following tracheostomy, timing and cause of death
- Adherence of tracheostomy procedure to national guidance [ Time Frame: 12 months ]Following PPE guidance
- Operator wellness [ Time Frame: 12 months ]Symptomatic or test positive COVID-19 infection in healthcare professionals involved in the tracheostomy procedure.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult patients
- Diagnosed with COVID-19
- Mechanically ventilated
- Undergoing elective surgical or percutaneous tracheostomy
- Health care professionals involved in the tracheostomy procedure (main operator and assistant)
Exclusion Criteria:
- COVID-19 patients undergoing an emergency tracheostomy;
- Patients younger than 18 years of age

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04572438
United Kingdom | |
University College London NHS Foundation Trust | |
London, United Kingdom |
Principal Investigator: | Nick JI Hamilton, MBChB PhD | University College, London |
Responsible Party: | University College, London |
ClinicalTrials.gov Identifier: | NCT04572438 |
Other Study ID Numbers: |
Z6364106/0000/00/00 |
First Posted: | October 1, 2020 Key Record Dates |
Last Update Posted: | May 18, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |